Targeting HER2 in Breast Cancer: Latest Developments on Treatment Sequencing and the Introduction of Biosimilars

2020/10/06 by Megan E. Tesch, Karen A. Gelmon · 22 citations
Medicine · Immunology and Microbiology · #HER2/EGFR in Cancer Research #Monoclonal and Polyclonal Antibodies Research #Biosimilars and Bioanalytical Methods

paper · doi:10.1007/s40265-020-01411-y

Citations

• Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate

Cited by

• Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors. [europepmc]
• Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody-drug conjugates in the breast cancer treatment landscape. [europepmc]
• Current and future landscape of targeted therapy in HER2-positive advanced breast cancer: redrawing the lines. [europepmc]
• MitoQ Prevents Human Breast Cancer Recurrence and Lung Metastasis in Mice. [europepmc]
• Novel Therapies for the Treatment of HER2-Positive Advanced Breast Cancer: A Canadian Perspective. [europepmc]
• Molecular Assessment of HER2 to Identify Signatures Associated with Therapy Response in HER2-Positive Breast Cancer. [europepmc]
• The efficacy of tucatinib-based therapeutic approaches for HER2-positive breast cancer. [europepmc]
• Systematic Review on the Use of Biosimilars of Trastuzumab in HER2+ Breast Cancer. [europepmc]
• Pathological complete remission of relapsed tumor by photo-activating antibody-mimetic drug conjugate treatment. [europepmc]
• Current challenges and unmet needs in treating patients with human epidermal growth factor receptor 2-positive advanced breast cancer. [europepmc]
• Neutrophil extracellular traps (NETs)-related lncRNAs signature for predicting prognosis and the immune microenvironment in breast cancer. [europepmc]
• Targeted RASSF1A expression inhibits proliferation of HER2‑positive breast cancer cells in vitro . [europepmc]
• Efficacy and safety of disitamab vedotin after trastuzumab for HER2 positive breast cancer: a real-world data of retrospective study. [europepmc]
• Current advance of nanotechnology in diagnosis and treatment for malignant tumors. [europepmc]
• Expanding treatment options for patients with HER2+ metastatic breast cancer with margetuximab plus chemotherapy: a case report series. [europepmc]
• QL1701 (a proposed trastuzumab biosimilar) versus reference trastuzumab plus docetaxel as first-line therapy for HER2-positive metastatic breast cancer: a multicenter, randomized, double-blinded, parallel-controlled, phase III equivalence trial. [europepmc]
• Potential of epithelial membrane protein 3 as a novel therapeutic target for human breast cancer. [europepmc]
• Comparative Preclinical Evaluation of Tuznue Versus Referent Herceptin: A Registered Trastuzumab Biosimilar. [europepmc]
• Pharmacokinetic bioequivalence of the fixed-dose combination of pertuzumab and trastuzumab administered subcutaneously using a handheld syringe or an on-body delivery system. [europepmc]
• Identification of novel HER2 ınhibitors: potential therapeutics for breast cancer. [europepmc]
• Enhanced HER-2 prediction in breast cancer through synergistic integration of deep learning, ultrasound radiomics, and clinical data. [europepmc]
• Delayed Cardiac Dysfunction During Prolonged Use of Trastuzumab for the Treatment of HER2-Positive Metastatic Breast Cancer. [europepmc]